A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)
Active, not recruiting
Phase 1 Results N/ASummary of Purpose
The purpose of this study is to evaluate the safety and tolerability of 42037788 (CNTO 0007) in patients who have suffered a stroke. The study is not designed to establish efficacy, although preliminary explorations will be conducted.
Read More →Trial Milestones
The following dates are available for this trial. Trial information last updated on 3 June 2013.
| 1 Dec 2010 | 7 Jan 2011 | Unavailable | 1 Sep 2013 | 1 Jun 2013 | Unavailable |
| Start Date | First Received | 1st Completion | Completion | Verification | Results |
|---|
Trial Basics
Interventions
Conditions
Sponsors
Trial Design
- Allocation: Randomized
- Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
- Purpose: Treatment
- Endpoint: Safety Study
- Intervention: Single Group Assignment
Contacts
- Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:
View Trial Locations
Recruitment
- Enrollment: 13
- Gender: Both
- Minimum Age: 18 Years
- Accepts Healthy Volunteers: No
- 22 locations, 2 countries
Principal Investigators
- Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Janssen Research & Development, LLC C. Clinical Trial
Janssen Research & Development, LLC
